

EMBRACE THE POWER OF TIME



THE SMARTT Y90 PROGRAMME

SIRT Multidisciplinary AppRoach with TheraSphere™ Therapy

A unique peer-to-peer educational programme that explores how personalised and versatile TheraSphere Y-90 Therapy can achieve tumour response and preserve liver function in patients at various stages of unresectable HCC





THE SMARTT Y90 PROGRAMME

SIRT Multidisciplinary AppRoach with TheraSphere™ Therapy

The SMARTT Y90 Programme is unique peer-to-peer educational initiative exploring the treatment of liver cancer, with a focus on controlling and downstaging HCC.

This is an ambitious long-term initiative, through which we are building a dynamic, interactive forum of hepatologists and other liver cancer specialists to explore the role of personalised TheraSphere Y-90 Therapy as a **versatile and well-tolerated treatment, proven to achieve high tumour response and downstaging rates while preserving liver function.**

Steering Committee


The programme has been developed in co-operation with multi-disciplinary specialists who will take an active role in the delivery of the curriculum.




Dr. Sherrie Bhoori
Hepatologist,
Milan, Italy




Dr. Maria Varela
Hepatologist,
Oviedo, Spain



Prof. Deniz Balci
HPB & Transplant
Surgeon, Istanbul,
Turkey



Prof. Riad Salem
Interventional
Radiologist,
Chicago, IL USA



Prof. Eric Vibert
Liver Transplant
Surgeon,
Villejuif, France



Prof. Etienne Garin
Nuclear Medicine
Physician,
Rennes, France




Prof. Dirk Arnold
Medical Oncologist,
Hamburg, Germany




Dr. Irene Bargellini
Interventional
Radiologist,
Turin, Italy



Dr. David Pinato
Medical Oncologist,
London, UK



Dr. José Martínez
Interventional
Radiologist,
Valencia, Spain



Prof. Boris Guiu
Interventional
Radiologist,
Montpellier, France

Additional faculty members include:





THE SMARTT Y90 CURRICULUM OVERVIEW 2024/2025

Evolving Multidisciplinary Treatment Strategies in Primary Liver Tumours Advancing Patient Outcomes with TheraSphere Y-90 Therapy

SMARTT Y90 Academy
Ask, Learn and Explore HCC Care



Ask-the-Experts

A customised one-to-one confidential virtual exchange with top experts specialised in primary liver cancer.



Learning Hub

A personalised educational experience, designed to meet individual preferences across primary liver cancer specialties.



HCC Clinical Guide

A concise TheraSphere Y-90 Therapy clinical guide dedicated for hepatologists, gastroenterologists, medical oncologists and HPB Liver Transplant Surgeons.

Workshop 1
broadcast on
12 June 2024



1 hour

Improving survival in primary liver cancer: treatment strategies with TheraSphere Y-90 Therapy

Prof. Boris Guiu
Interventional Radiologist,
Montpellier, France

Curative Surgery and Locoregional Neoadjuvant Therapies in HCC

Prof. Eric Vibert
Liver Transplant Surgeon,
Villejuif, France

SIRT Treatment approach in downstaging HCC and the impact on clinical outcomes

Prof. Etienne Garin
Nuclear Medicine Physician,
Rennes, France

Multidisciplinary treatment strategies for HCC - the medical oncologist perspective

Dr. David Pinato
Medical Oncologist,
London, UK

Livestream Workshop 2
on
Sept 2024



Challenging HCC Treatment Strategies in a Tumour Board Live discussion

2025 Curriculum

The 2025 programme will feature livestream activity and face-to-face local meetings, including a European summit meeting.



Register now for SMARTT Y90 first workshop

Join the first workshop



ABOUT THERASPHERE™ Y-90 THERAPY


The most powerful SIRT therapy available, the TheraSphere Y-90 dose can be personalised to each patient to deliver highly targeted radiation to the tumour(s) while preserving healthy liver tissue.

Twenty years of clinical evidence supports the efficacy of TheraSphere Y-90 throughout the HCC treatment pathway – including as a valuable neoadjuvant therapy that can downstage and bridge patients to curative options.¹

The EPOCH phase III RCT demonstrated a positive progression-free survival benefit when TheraSphere Y-90 is used with systemic treatment in patients with metastatic liver tumours after failed first-line therapy,² while the importance of its role in the treatment of intrahepatic cholangiocarcinoma is increasingly widely recognised.³

HCC Case Example

Unlocking Access to Curative Surgery with Therasphere: Effective Disease Control and Increased FLR




Baseline

12cm HCC in segments 5 and 8 with portal vein thrombosis



10 months post TheraSphere Y90 therapy

Atrophy of the treated right lobe with hypertrophy of the left lobe (FLR), allowing right hepatectomy to be performed



Post surgery

CT at day six post right hepatectomy

Images: Courtesy of Professor Eric Vibert, MD, PhD, IKO, Hepatobiliary Surgeon, Paul Brousse University Hospital, Villejuif, France, reproduced with permission

References: **1.** Lewandowski JR, Johnson GE, Kim E, et al. Use of Yttrium-90 (Y90) Glass Microspheres (TheraSphere™) as Neoadjuvant to Transplantation/Resection in Hepatocellular Carcinoma: Analyses from the LEGACY Study. *J Clin Oncol* 2021;39(3) suppl 300. **2.** Mulcahy MF, Mahvash A, Pracht M, et al. Radioembolization with Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. *J Clin Oncol* 2021: Jco2101839. **3.** Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. *JAMA Oncol.* 2020;6(1):51–59. doi:10.1001/jamaoncol.2019.3702.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

2023 Copyright. © Boston Scientific Corporation or its affiliates. All rights reserved. PI-1649308-AB.